MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/cancers18040554

Медицинская библиотека · Cancers · 2026

Epidemiology, Comorbidities and Associated Treatments, Therapeutic Management, and Clinical Outcomes in Patients with Prostate Cancer in Spain (SRealProstate): A Real-World Cohort Study.

Borque-Fernando Angel, Romero-Laorden Nuria, Rodríguez-Moreno Juan Francisco, Alfaro-Oliver Noelia, Beliera-Kiendl Ariela, Rebollo-Gómez Elena, Hernández Ignacio, Rubio-Briones Jose

СтатьяПеревод в очереди

Аннотация

Background/

Objectives

Prostate cancer (PC) is the most prevalent cancer in men in Spain. Clinical management depends on the stage/tumor response to therapy/therapy availability. Given the limited national data, we analyzed real-world prevalence and management patterns.

Methods

This was an observational, retrospective study using electronic medical records from public primary care centers/hospitals in Spain (BIG-PAC® database), between 1 June 2014, and 31 December 2021. Adult PC-diagnosed patients were classified into localized PC with no compromised lymph nodes and no metastasis (N0/M0), locally advanced PC with compromised lymph nodes, no metastasis (N1/M0), metastatic hormone-sensitive PC (mHSPC), non-metastatic castration-resistant PC (nmCRPC), and metastatic castration-resistant PC (mCRPC, categorized by treatment line). Progression across stages was recorded. All analyses were descriptive and exploratory.

Results

A total of 19,224 patients met the inclusion criteria. The five-year PC prevalence was 590 cases/100,000 males; localized PC was the most prevalent form of cancer (PC[N0/M0]: 473/100,000; PC[N1/M0]: 78/100,000), followed by mCRPC (16/100,000), mHSPC (14/100,000), and nmCRPC (8/100,000). We further analyzed 5583 patients with progression. Surgery was performed in 61.7% PC (N1/M0), while radiotherapy was used in 24.3%. Taxanes were used in 52.4% of the mHSPC patients. First prescription options for mCRPC L1 and L2 were androgen receptor pathway inhibitors (55.9% and 49.7%); 44.9% of mCRPC L3 and 83.3% of L4+ (≥4 treatment lines) patients used taxanes. Analgesics were common in mHSPC, nmCRPC, and mCRPC patients. Few mHSPC patients died without progression (11.6%); 90.2% and 56.2% of the mCRPC patients received first- and second-line treatments, respectively. During follow-up, 2436 patients died. Cardiovascular comorbidities increased with stage.

Conclusions

PC management in Spain varies substantially by disease stage. Advanced disease was associated with higher comorbidity burden and reduced survival in mHSPC and mCRPC patients, despite multiple available treatments.

Для цитирования: Borque-Fernando Angel, Romero-Laorden Nuria, Rodríguez-Moreno Juan Francisco, Alfaro-Oliver Noelia, Beliera-Kiendl Ariela, Rebollo-Gómez Elena, Hernández Ignacio, Rubio-Briones Jose. Epidemiology, Comorbidities and Associated Treatments, Therapeutic Management, and Clinical Outcomes in Patients with Prostate Cancer in Spain (SRealProstate): A Real-World Cohort Study.. Cancers. 2026. DOI: 10.3390/cancers18040554.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.